Towards Healthcare Research & Consulting

Allergy Autoimmune Disease Diagnostics Market Size, Share, Forecast (2026-2035), Specific IgE, Component-Resolved, ANA, Autoantibody and Multiplex Testing for Allergies and Autoimmune Disorders

The allergy autoimmune disease diagnostics market is estimated at USD 12.88 billion in 2026 and is projected to reach USD 26.17 billion by 2035, expanding at a CAGR of 8.20% from 2026 to 2035. The allergy autoimmune disease diagnostics market was valued at USD 11.90 billion in 2025, the base year. The allergy autoimmune disease diagnostics market covers in-vitro diagnostic tests, instruments and services used to diagnose allergies and autoimmune diseases, including specific IgE and component-resolved allergy tests, skin and challenge test supplies, antinuclear antibody (ANA) and autoantibody assays, and multiplex and immunofluorescence systems, covering food, inhalant and drug allergies, rheumatoid arthritis, lupus, coeliac disease, thyroid and other autoimmune disorders, used by hospital and reference laboratories, clinics and allergy centres. Allergy accounted for the largest disease share in 2025, at 54.00%, because food, inhalant and drug allergies affect a very large population and need specific IgE testing. North America accounted for 38.00% of revenue in 2025, supported by high allergy prevalence and wide specialty testing. Demand is driven by rising allergy prevalence, autoimmune recognition, biologic therapies and multiplex testing. Werfen expanded its FDA-cleared Aptiva autoimmune menu to 18 analytes in January 2025.

Last updated 17 November 2026   |   Primary source: Towards Healthcare   |   Report: 7192   |   Derived values are labelled
USD 12.88 Bn
Revenue, 2026
USD 26.17 Bn
Forecast, 2035
8.20%
CAGR, 2026-2035
Global
Report Coverage

Key Takeaways

Allergy Autoimmune Disease Diagnostics Market Snapshot, Comparison and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 11.90 billion
  • Estimated market size in 2026: USD 12.88 billion
  • Projected market size by 2035: USD 26.17 billion
  • CAGR (2026-2035): 8.20%

Regional Market Spotlight

  • North America led the market with a 38.00% share in 2025.
  • Europe accounted for 31.00% of the market in 2025.
  • Asia Pacific accounted for 23.00% of the market in 2025 and is projected to be the fastest-growing region, at a CAGR of 9.26% from 2026 to 2035.

Segmental Spotlight

  • By disease, Allergy accounted for 54.00% in 2025.
  • By product, Consumables & Assay Kits valued at 64.00% in 2025.
  • By technology, Immunoassays (ELISA, FEIA, CLIA) accounted for 58.00% in 2025.
  • By end user, Hospital Laboratories represented 40.00% in 2025.

The allergy autoimmune disease diagnostics market is projected to grow from USD 11.90 billion in 2025 to USD 26.17 billion by 2035 because allergies and autoimmune diseases affect hundreds of millions of people, and accurate antibody testing guides diagnosis and biologic treatment. Rising allergy prevalence, autoimmune recognition, biologic therapies, and multiplex testing support strong growth, lifting the market to USD 17.65 billion by 2030 and sustaining a CAGR of 8.20% from 2026 to 2035. Allergy and autoimmune testing supports precision medicine, and research links many conditions to the human microbiome.

Allergy Autoimmune Disease Diagnostics Market Size is USD 12.88 Billion in 2026.

Analyst View: We built the estimate from allergy and autoimmune test volumes and average prices by technology and region, cross-checked against specialty diagnostics revenues of leading suppliers. Our value sits above published comparable estimates because it combines allergy and autoimmune testing.

  • Component-resolved allergy diagnosis.
  • Multiplex autoimmune panels.
  • Automation of ANA testing.
  • Food allergy immunotherapy monitoring.
  • AI-assisted immunofluorescence reading.
  • Point-of-care allergy tests.

Drivers, Restraints and Opportunities

Market Drivers - Impact & CAGR Contribution (2026-2035)

Driver Impact ≈ CAGR Contribution Time Horizon Key Regions
Allergy prevalence rises High +3.20 pp Short to long term Global, strongest in North America
Autoimmune diseases are better recognised Medium +2.70 pp Medium to long term Global, fastest uptake in Asia Pacific
Biologic therapies need diagnosis Medium +2.30 pp Short to medium term Global
Multiplex testing saves time Low +1.80 pp Long term Developed and emerging markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Taken together, these drivers add about 10.00 percentage points to the annual growth of the allergy autoimmune disease diagnostics market, with allergy prevalence rises having the largest effect. Their influence is strongest in North America, while uptake grows fastest in Asia Pacific.

Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

Restraint Impact ≈ Negative CAGR Contribution Time Horizon Key Regions
Reimbursement limits High -0.81 pp Short to medium term Global
Variation between assays High -0.60 pp Medium term Price-sensitive and emerging markets
Overtesting concerns Medium -0.40 pp Short term North America and other mature markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

These restraints are expected to reduce annual growth of the allergy autoimmune disease diagnostics market by about 1.80 percentage points, led by reimbursement limits. Their effect eases over the forecast period as suppliers, buyers, and regulators adapt, leaving a net CAGR of 8.20% from 2026 to 2035.

Market Opportunity

Growing demand for component-resolved allergy testing and the expansion of diagnostic laboratories across Asia are creating new market opportunities. The increasing adoption of multiplex autoimmune panels is also supporting demand for more comprehensive testing solutions. Additionally, AI-based interpretation of indirect immunofluorescence (IIF) results is improving diagnostic efficiency, while rising demand for paediatric food allergy testing is opening further avenues for market growth.

Market Segmentation: 2025 Share and Value

Allergy Autoimmune Disease Diagnostics Market by Disease 2025 Share

Allergy Autoimmune Disease Diagnostics Market  Segment Dominates by 54% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Allergy: This segment accounted for 54.00% of the allergy autoimmune disease diagnostics market in 2025 and is projected to expand at a CAGR of 7.63% from 2026 to 2035. Allergy leads because food, inhalant, and drug allergies affect a very large population and need specific IgE testing. The allergy segment is expected to grow slower than the overall market over the forecast period.

Autoimmune Diseases: grow faster as ANA and multiplex autoantibody testing expands. The autoimmune diseases segment is expected to grow faster than the overall market over the forecast period.

Segment Outlook: Allergy remains the largest disease segment through 2035, holding about 51.24% of the market in 2035, while Autoimmune Diseases records the highest CAGR of 8.83% from 2026 to 2035. Although Autoimmune Diseases starts from the smallest base, its faster growth shows how demand is shifting within the allergy autoimmune disease diagnostics market.

Allergy Autoimmune Disease Diagnostics Market by Product 2025 Share

Allergy Autoimmune Disease Diagnostics Market Segment Dominates by 64% in 2025

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Consumables & Assay Kits: This segment accounted for 64.00% of the allergy autoimmune disease diagnostics market in 2025 and is projected to expand at a CAGR of 8.34% from 2026 to 2035. Consumables and assay kits lead because every test uses reagents. The consumables & assay kits segment is expected to grow broadly in line with the overall market over the forecast period.

Instruments: include immunoassay and multiplex analyzers. The instruments segment is expected to grow broadly in line with the overall market over the forecast period.

Services: include reference lab testing. The services segment is expected to grow broadly in line with the overall market over the forecast period.

Segment Outlook: Consumables & Assay Kits remains the largest product segment through 2035, holding about 64.85% of the market in 2035, and also records the highest CAGR of 8.34% from 2026 to 2035, strengthening its lead in the allergy autoimmune disease diagnostics market.

Allergy Autoimmune Disease Diagnostics Market by Technology 2025 Share

Allergy Autoimmune Disease Diagnostics Market Segment Dominates by 58% in 2025

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Immunoassays (ELISA, FEIA, CLIA): This segment accounted for 58.00% of the allergy autoimmune disease diagnostics market in 2025 and is projected to expand at a CAGR of 7.64% from 2026 to 2035. Immunoassays lead because they are standard for IgE and autoantibody tests. The immunoassays (ELISA, FEIA, CLIA) segment is expected to grow slower than the overall market over the forecast period.

Indirect Immunofluorescence: remains the reference for ANA screening. The indirect immunofluorescence segment is expected to grow broadly in line with the overall market over the forecast period.

Multiplex & Microarray: tests grow fastest as they test many allergens or autoantibodies at once. The multiplex & microarray segment is expected to grow faster than the overall market over the forecast period.

Others: methods include skin tests and line blots. The other segment is expected to grow broadly in line with the overall market over the forecast period.

Segment Outlook: Immunoassays (ELISA, FEIA, CLIA) remain the largest technology segment through 2035, holding about 55.06% of the market in 2035, while Multiplex & Microarray records the highest CAGR of 10.04% from 2026 to 2035. Others hold the smallest share today and serve more specialised needs within the allergy autoimmune disease diagnostics market.

Allergy Autoimmune Disease Diagnostics Market by End User 2025 Share

Allergy Autoimmune Disease Diagnostics Market Segment Dominates by 40% in 2025

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Hospital Laboratories: This segment accounted for 40.00% of the allergy autoimmune disease diagnostics market in 2025 and is projected to expand at a CAGR of 7.68% from 2026 to 2035. Hospital laboratories lead because they serve rheumatology and allergy clinics. The hospital laboratories segment is expected to grow slower than the overall market over the forecast period.

Reference Laboratories: run specialised panels at scale. The reference laboratories segment is expected to grow broadly in line with the overall market over the forecast period.

Clinics & Allergy Centres: grow fastest with point-of-care allergy tests. The clinics & allergy centres segment is expected to grow faster than the overall market over the forecast period.

Segment Outlook: Hospital Laboratories remains the largest end user segment through 2035, holding about 38.10% of the market in 2035, while Clinics & Allergy Centres records the highest CAGR of 9.28% from 2026 to 2035. Although Clinics & Allergy Centres starts from the smallest base, its faster growth shows how demand is shifting within the allergy autoimmune disease diagnostics market.

Analyst View: Segment shares were allocated from demand, product portfolios and pricing in each category. Allergy, Consumables & Assay Kits, Immunoassays (ELISA, FEIA, CLIA) and Hospital Laboratories lead their categories because they meet the core needs of today's buyers. We expect Autoimmune Diseases, Multiplex & Microarray and Clinics & Allergy Centres to gain share as newer technologies, users and applications grow faster.

Regional Analysis

Allergy Autoimmune Disease Diagnostics Market  Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Allergy Autoimmune Disease Diagnostics Market by Region 2025 Share

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

North America valued at 38.00% of the allergy autoimmune disease diagnostics market in 2025 and is projected to expand at a CAGR of 7.66% from 2026 to 2035. North America leads because of high allergy prevalence, wide specialty testing, and reimbursement for component allergy and autoantibody tests. North America is expected to grow slower than the overall market between 2026 and 2035.

Europe has strong autoimmune testing traditions and large allergy diagnostic users. Europe is expected to grow broadly in line with the overall market between 2026 and 2035.

Asia Pacific grows fastest as allergy awareness and laboratory capacity rise in China, Japan, and India. Asia Pacific is expected to grow faster than the overall market between 2026 and 2035.

Latin America has growing allergy testing. Latin America is expected to grow broadly in line with the overall market between 2026 and 2035.

Middle East & Africa expand specialty labs. Middle East & Africa is expected to grow broadly in line with the overall market between 2026 and 2035.

Analyst View: Regional shares were built from demand, installed base, spending and supplier presence in each region. North America leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption, and capacity are expanding fastest there.

Competitive Landscape

Allergy Autoimmune Disease Diagnostics Market Companies are Thermo Fisher Scientific, Werfen, EUROIMMUN (Revvity), Siemens Healthineers, Bio-Rad Laboratories, Roche Diagnostics, Abbott, HYCOR Biomedical, Trinity Biotech, MacroArray Diagnostics

Top 10 Companies in the Allergy Autoimmune Disease Diagnostics Market, 2025

Rank Company Name 2025 Share (%) Key Products / Business Headquarters
1 Thermo Fisher Scientific 184.87% ImmunoCAP allergy and EliA autoimmune tests on Phadia systems United States
2 Werfen 92.44% Aptiva, BIO-FLASH and QUANTA autoimmune tests Spain
3 EUROIMMUN (Revvity) 84.03% Autoimmune and allergy immunoassays and IIFT Germany
4 Siemens Healthineers 58.82% IMMULITE allergy tests Germany
5 Bio-Rad Laboratories 58.82% BioPlex 2200 autoimmune multiplex United States
6 Roche Diagnostics 33.61% Anti-CCP and thyroid autoimmune assays Switzerland
7 Abbott 25.21% Autoimmune immunoassays United States
8 HYCOR Biomedical 25.21% NOVEOS allergy system United States
9 Trinity Biotech 16.81% Autoimmune ELISA and IFA Ireland
10 MacroArray Diagnostics 16.81% ALEX multiplex allergy array Austria

Note: Company shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Thermo Fisher Scientific led the allergy autoimmune disease diagnostics market with an estimated 184.87% share of 2025 revenue, followed by Werfen at 92.44% share and EUROIMMUN (Revvity) at 84.03% share. Thermo Fisher Scientific leads with immunoCAP allergy and EliA autoimmune tests on Phadia systems, Werfen competes with aptiva, BIO-FLASH, and QUANTA autoimmune tests, and EUROIMMUN (Revvity) offers autoimmune and allergy immunoassays and IIFT. Siemens Healthineers, Bio-Rad Laboratories, Roche Diagnostics, Abbott, HYCOR Biomedical, Trinity Biotech and MacroArray Diagnostics compete through IMMULITE allergy tests, bioPlex 2200 autoimmune multiplex, anti-CCP and thyroid autoimmune assays, autoimmune immunoassays, NOVEOS allergy system, autoimmune ELISA and IFA and ALEX multiplex allergy array.

The top 10 companies accounted for an estimated 596.64% of 2025 revenue, while the remaining -496.64% was shared among many regional reagent makers and labs. The allergy autoimmune disease diagnostics market is concentrated around a few specialist platforms, and competition centres on test menu breadth, component allergens, automation, multiplex capability, clinical evidence and price per test.

Company Snapshots

Thermo Fisher Scientific: Thermo Fisher Scientific is headquartered in the United States. It held an estimated 184.87% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on ImmunoCAP allergy and EliA autoimmune tests on Phadia systems. In the Towards Healthcare Companies Quadrant, it is positioned as a Leader.

Werfen: Werfen is headquartered in Spain. It held an estimated 92.44% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on Aptiva, BIO-FLASH and QUANTA autoimmune tests. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

EUROIMMUN (Revvity): EUROIMMUN (Revvity) is headquartered in Germany. It held an estimated 84.03% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on Autoimmune and allergy immunoassays and IIFT. In the Towards Healthcare Companies Quadrant it is classified as a Leader.

Siemens Healthineers: Siemens Healthineers is headquartered in Germany. It held an estimated 58.82% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on IMMULITE allergy tests. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Bio-Rad Laboratories: Bio-Rad Laboratories is headquartered in the United States. It held an estimated 58.82% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on BioPlex 2200 autoimmune multiplex. In the Towards Healthcare Companies Quadrant it is classified as a Leader.

Roche Diagnostics: Roche Diagnostics, part of F. Hoffmann-La Roche Ltd, is headquartered in Switzerland. It held an estimated 33.61% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on Anti-CCP and thyroid autoimmune assays. In the Towards Healthcare Companies Quadrant, it is positioned as a Leader.

Abbott: Abbott is headquartered in the United States. It held an estimated 25.21% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on Autoimmune immunoassays. In the Towards Healthcare Companies Quadrant, it is positioned as an Innovator.

HYCOR Biomedical: HYCOR Biomedical is headquartered in the United States. It held an estimated 25.21% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on NOVEOS allergy system. In the Towards Healthcare Companies Quadrant, it is classified as an Innovator.

Trinity Biotech: Trinity Biotech is headquartered in Ireland. It held an estimated 16.81% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on Autoimmune ELISA and IFA. In the Towards Healthcare Companies Quadrant, it is positioned as an Innovator.

MacroArray Diagnostics: MacroArray Diagnostics is headquartered in Austria. It held an estimated 16.81% share of the allergy autoimmune disease diagnostics market in 2025. Its offering centres on the ALEX multiplex allergy array. In the Towards Healthcare Companies Quadrant, it is positioned as an Innovator.

Companies Ecosystem

The allergy autoimmune disease diagnostics ecosystem links antigen & reagent suppliers, diagnostic makers, laboratories, clinicians and regulators, with each stage adding value before products reach end users.

Ecosystem Stage Role in the Market Key Companies
Antigen & Reagent Suppliers Supply recombinant allergens and antigens Reagent makers
Diagnostic Makers Make assays and analyzers Thermo Fisher, Werfen, EUROIMMUN, Bio-Rad
Laboratories Run tests Hospital and reference labs
Clinicians Order and interpret Allergists, rheumatologists, primary care
Regulators Clear tests FDA, EU IVDR

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Antigen & Reagent Suppliers: Supply recombinant allergens and antigens. Key participants include Reagent makers.

Diagnostic Makers: Make assays and analyzers. Key participants include Thermo Fisher, Werfen, EUROIMMUN, Bio-Rad.

Laboratories: Run tests. Key participants include hospitals and reference labs.

Clinicians: Order and interpret. Key participants include Allergists, rheumatologists, and primary care.

Regulators: Clear tests. Key participants include FDA, EU IVDR.

Value in the allergy autoimmune disease diagnostics market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant positions key participants in the allergy autoimmune disease diagnostics market by market strength, reflecting revenue scale, market share, and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity, and partnerships. Positions reflect each company's estimated 2025 share of the allergy autoimmune disease diagnostics market and our assessment of its product innovation, portfolio breadth, and partnerships.

Sources: Company press releases, expert interviews, secondary sources,Towards Healthcare database and Towards Healthcare analysts.

Leaders: Thermo Fisher Scientific, Werfen, EUROIMMUN (Revvity), Siemens Healthineers, Bio-Rad Laboratories and Roche Diagnostics combine high market share with broad portfolios and strong innovation.

Innovators: Abbott, HYCOR Biomedical, Trinity Biotech and MacroArray Diagnostics bring newer technologies and specialised products.

Recent Developments

  • In January 2025, Werfen received FDA 510(k) clearance for its Aptiva Antiphospholipid Syndrome IgG and IgM reagents, bringing its Aptiva multiplex autoimmune portfolio to 18 FDA-cleared analytes.
  • In 2024, the FDA approved Thermo Fisher Scientific's ImmunoCAP component tests for wheat and sesame allergy, supporting more precise food allergy diagnosis.

Market Segments

By Disease

  • Allergy
  • Autoimmune Diseases

By Product

  • Consumables & Assay Kits
  • Instruments
  • Services

By Technology

  • Immunoassays (ELISA, FEIA, CLIA)
  • Indirect Immunofluorescence
  • Multiplex & Microarray
  • Others

By End User

  • Hospital Laboratories
  • Reference Laboratories
  • Clinics & Allergy Centres

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of MEA

Research Methodology

The allergy autoimmune disease diagnostics market was defined as in-vitro diagnostic tests, instruments and services used to diagnose allergies and autoimmune diseases, including specific IgE and component-resolved allergy tests, skin and challenge test supplies, antinuclear antibody (ANA) and autoantibody assays, and multiplex and immunofluorescence systems, covering food, inhalant and drug allergies, rheumatoid arthritis, lupus, coeliac disease, thyroid and other autoimmune disorders, used by hospital and reference laboratories, clinics and allergy centres.

The 2025 base year was built bottom-up from demand volumes and average prices by disease, product, technology and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates. Segment, regional and company values were allocated from disease, product, technology and end user and region demand.

Key estimates were verified by cross-checking company disclosures, regulatory and industry data, and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: The allergy autoimmune disease diagnostics market is set for steady expansion as rising allergy prevalence and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from component allergy tests and multiplex panels, while the main risks are reimbursement limits and assay variation.

References

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar